Comparative Pharmacology
Head-to-head clinical analysis: ANJESO versus OXAPROZIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANJESO versus OXAPROZIN.
ANJESO vs OXAPROZIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which results in anti-inflammatory, analgesic, and antipyretic effects.
120 mg administered intravenously over 15 minutes, followed by 30 mg intravenously over 15 minutes, with the second dose given 12 to 24 hours after the first dose.
600-1200 mg orally once daily; maximum 1800 mg/day.
None Documented
None Documented
Clinical Note
moderateOxaprozin + Gatifloxacin
"Oxaprozin may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateOxaprozin + Rosoxacin
"Oxaprozin may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateOxaprozin + Levofloxacin
"Oxaprozin may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateOxaprozin + Trovafloxacin
"Oxaprozin may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is 1.5-2.5 hours in healthy adults. In elderly or renally impaired patients, half-life may extend to up to 6 hours.
Terminal elimination half-life is approximately 50–60 hours in healthy adults; clinical context: once-daily dosing achieves steady-state in 7–10 days.
Approximately 70% renal (30% unchanged, 40% as glucuronide conjugate), 30% fecal/biliary.
Primarily hepatic metabolism (glucuronidation and hydroxylation) with renal excretion of metabolites; less than 1% excreted unchanged in urine; fecal elimination accounts for ~20%.
Category C
Category D/X
NSAID
NSAID